Product Description
Betta is developing bpi-16350, an Oral CDK Inhibitor for Advanced Solid Cancer. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03791112)
Mechanisms of Action: CDK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Betta Pharm
Company Location: Asia Pacific
Company Founding Year: 2003
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Breast Cancer
Phase 1: Healthy Volunteers|Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03791112 |
BTP-66711 | P1 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2025-12-01 |
12% |
2025-01-28 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
CTR20230856 |
CTR20230856 | P1 |
Completed |
Oncology Solid Tumor Unspecified|Healthy Volunteers |
2024-03-29 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20182494 |
CTR20182494 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20221037 |
CTR20221037 | P3 |
Active, not recruiting |
Breast Cancer |
None |
2025-04-29 |
Patient Enrollment|Treatments |
Recent News Events
Date |
Type |
Title |
|---|